Article
Gatifloxacin approved
Author(s):
CA-The FDA approval of gatifloxacin ophthalmic solution 0.3% (Zymar, Allergan) marks a milestone as the first fourth-generation fluoroquinolone to enter the ophthalmic market. The therapy for the treatment of bacterial conjunctivitis caused by susceptible strains of bacteria also has a unique mechanism to prevent development of antibiotic resistance, according to Allergan.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
